- Home
- ATOS vs ASPS Comparison
ATOS vs ASPS Comparison
Compare ATOS & ASPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATOS
- ASPS
- Stock Information
- Founded
- ATOS 2009
- ASPS 1999
- Country
- ATOS United States
- ASPS Luxembourg
- Employees
- ATOS N/A
- ASPS N/A
- Industry
- ATOS Biotechnology: Pharmaceutical Preparations
- ASPS Other Consumer Services
- Sector
- ATOS Health Care
- ASPS Consumer Discretionary
- Exchange
- ATOS Nasdaq
- ASPS Nasdaq
- Market Cap
- ATOS 120.4M
- ASPS 104.5M
- IPO Year
- ATOS 2012
- ASPS N/A
- Fundamental
- Price
- ATOS $0.86
- ASPS $9.00
- Analyst Decision
- ATOS Strong Buy
- ASPS
- Analyst Count
- ATOS 3
- ASPS 0
- Target Price
- ATOS $6.25
- ASPS N/A
- AVG Volume (30 Days)
- ATOS 1.3M
- ASPS 22.4K
- Earning Date
- ATOS 11-12-2025
- ASPS 10-23-2025
- Dividend Yield
- ATOS N/A
- ASPS N/A
- EPS Growth
- ATOS N/A
- ASPS N/A
- EPS
- ATOS N/A
- ASPS 0.00
- Revenue
- ATOS N/A
- ASPS $169,648,000.00
- Revenue This Year
- ATOS N/A
- ASPS $38.29
- Revenue Next Year
- ATOS N/A
- ASPS N/A
- P/E Ratio
- ATOS N/A
- ASPS $1,335.59
- Revenue Growth
- ATOS N/A
- ASPS 10.68
- 52 Week Low
- ATOS $0.55
- ASPS $3.46
- 52 Week High
- ATOS $1.66
- ASPS $15.96
- Technical
- Relative Strength Index (RSI)
- ATOS 39.96
- ASPS 25.08
- Support Level
- ATOS $0.86
- ASPS $9.34
- Resistance Level
- ATOS $0.91
- ASPS $12.24
- Average True Range (ATR)
- ATOS 0.05
- ASPS 0.68
- MACD
- ATOS -0.02
- ASPS -0.36
- Stochastic Oscillator
- ATOS 4.01
- ASPS 3.27
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.
About ASPS Altisource Portfolio Solutions S.A.
Altisource Portfolio Solutions SA is an integrated service provider and marketplace for the real estate and mortgage industries. It operates via two reportable segments, namely Servicer and Real Estate, which derive maximum revenue, and Origination. The Servicer and Real Estate segment provides loan servicers and real estate investors with solutions and technologies that span the mortgage and real estate lifecycle. The Origination segment provides originators with solutions and technologies that span the mortgage origination lifecycle. Altisource mainly serves financial institutions, government-sponsored enterprises, and originators in the United States, with the majority of its revenue flowing from field services and mortgage and real estate solutions.